About this trial
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.
Eligibility criteria
Qualifiers
Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.
Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.
Disqualifiers
Cognitive dysfunction, unable to complete the study (MMSE < 23)
Inability to tolerate levodopa shock test
Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases
Those with serious behavioral problems or mental disorders
Trial design
Treatments tested in this trial
- video recording
Treatment groups
7
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Ruijin Hospital
Collaborator
Nanjing Medical University
Collaborator
Second Affiliated Hospital of Soochow University
Collaborator
Beijing Hospital
Collaborator
Fujian Medical University Union Hospital
Collaborator
Guangdong Provincial People's Hospital
Collaborator
West China Hospital
Collaborator
The First Affiliated Hospital of Dalian Medical University
Collaborator
China-Japan Union Hospital, Jilin University
Collaborator
Renmin Hospital of Wuhan University
Collaborator
First Affiliated Hospital of Chongqing Medical University
Collaborator
Second Affiliated Hospital of Nanchang University
Collaborator
Xijing Hospital
Collaborator
The Affiliated Hospital of Qingdao University
Collaborator
The Second Affiliated Hospital of Xinjiang Medical University
Collaborator
Shenzhen People's Hospital
Collaborator
Tianjin Medical University General Hospital
Collaborator
Qilu Hospital of Shandong University
Collaborator
The First People's Hospital of Yunnan
Collaborator
The First Hospital of Jilin University
Collaborator
Tianjin Huanhu Hospital
Collaborator
The First Affiliated Hospital of Anhui Medical University
Collaborator
Wannan Medical College Yijishan Hospital
Collaborator
The Affiliated Hospital of Xuzhou Medical University
Collaborator